Plain-English translation of NCT07498218 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing VELGRAFT, a living cellular construct (a specially designed treatment made from living cells), to see if it can help heal chronic diabetic foot ulcers that have started to form healthy tissue. The study will enroll up to 24 patients and compare the new treatment to standard wound care over 12 weeks, then follow participants for another 12 weeks to see how well the wounds heal.
Diabetic foot ulcers are serious wounds that don't always heal well with standard dressings alone, sometimes leading to infection or amputation. This trial exists to find out whether this medication — a living cellular treatment — might help these wounds heal better and faster.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive either the new living cell treatment or standard wound care once a week for 12 weeks during clinic visits. The study is divided into two parts: the first part tests different amounts of the treatment to find the safest dose, and the second part compares the chosen dose to standard care in more patients. After the 12-week treatment phase, you will have a final follow-up visit at 24 weeks to see how your wound is healing. Your total participation will last up to about 6 months.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States